Eligibility Criteria

All participants at least 18 years old.

Inclusion Criteria:

1. Age ≥ 18 years, no gender limitation;

2. Patients with locally advanced pancreatic cancer diagnosed by cell / histopathology,
either initially diagnosed or previously treated;

3. The target lesion is not suitable for surgical resection, or the target lesion is
suitable for surgical resection but the patient gives up the surgical treatment and
chooses nano-knife combined with radiotherapy and chemotherapy

4. ECOG score is 0 ~ 2;

5. Expected survival ≥ 3 months;

6. Women of childbearing age must undergo a pregnancy test within 14 days prior to
enrollment, and those who have a negative result are eligible for enrollment. Men and
women of childbearing age and their sexual partners agreed to use reliable methods of
contraception before, during, and at least 90 days after the end of the study.

7. Full informed consent and signed informed consent.

Exclusion Criteria:

1. Patients suffering from active infection; high blood pressure (≥160 / 100mmHg) that
cannot be controlled by drugs; angina pectoris and unstable angina pectoris that have
begun in the last 3 months. Myocardial infarction and cardiac insufficiency occurred
within 1 year before enrollment ≥ NYHA Class II), schizophrenia, or history of
psychotropic substance abuse;

2. Patients with severe heart and lung insufficiency or intolerance to general
anesthesia;

3. Those who are allergic to CT and MRI contrast agents and unable to perform
preoperative three-phase dynamic enhanced scanning;

4. Ascites due to clinical symptoms, after 2 weeks of conservative medical treatment
(excluding drainage of ascites), the ascites still increases gradually;

5. Pregnant or lactating women;

6. HBV DNA ≥ 104 copies or ≥ 2000 IU / mL, antiviral liver protection treatment is
required before HBV-DNA



Source link